Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash.
August 2, 2025
by ACN Newswire
Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that the ...
August 5, 2021
by prnasia
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan, China FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
Everest Medicines announced today that the Taiwan, China Food and Drug Administration (FDA) has granted Pediatric and Rare Severe Disease Priority Review Designation for sacituzumab govitecan-hziy (SG).
July 29, 2021
by prnasia
Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China
Everest Medicines announced that it has entered into a strategic collaboration with MediTrust Health Co., Ltd, a leading innovative medical payment services provider and one of the largest pharmacy benefit management platforms in China.
July 21, 2021
by prnasia
Everest Medicines Announces Strategic Collaboration with Medbanks Health Technology to Develop Innovative Healthcare Service Solutions for Patients in China
Everest Medicines announced that it has entered into a strategic collaboration with Medbanks Health Technology, a pharmacy and healthcare services provider specializing in oncology.
July 14, 2021
by prnasia
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories
Everest Medicines announced that Spero Therapeutics, Inc., entered into a regional licensing agreement with Pfizer Inc. for SPR206.
July 6, 2021
by prnasia
Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Greater China and other parts of Asia, announced today that the China National Medical Products Administration (NMPA) ...
May 17, 2021
by prnasia
Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer
Everest Medicines announced today the appointment of Dr. Jennifer Yang as chief scientific officer. Dr. Yang has two decades of leadership experience in drug discovery and development at global pharmaceutical companies.
April 15, 2021
by prnasia
Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that the ...
April 2, 2021
by prnasia
Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava(TM) for the Treatment of Complicated Intra-abdominal Infections
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that the ...
March 22, 2021
by prnasia
Everest to offer two Arena Pharma drugs in Asian countries
US-based Arena Pharmaceuticals formed a development and commercialisation alliance with Chinese C-Bridge Capital-backed Everest Medicines for offering ralinepag and etrasimod in selected Asian countries.
December 8, 2017
by pharmaceutical-technology